Key findings from the UKCCMP cohort of 877 patients with haematological malignancy and COVID-19: disease control as an important factor relative to recent chemotherapy or anti-CD20 therapy.

Autor: Booth S; Oxford NIHR Biomedical Research Centre, Department of Haematology, Churchill Hospital, Oxford, UK., Curley HM; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Varnai C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Centre for Computational Biology, University of Birmingham, Birmingham, UK., Arnold R; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK., Lee LYW; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Department of Oncology, Oxford University, Oxford, UK., Campton NA; Institute of Translational Medicine, Birmingham Health Partners, Birmingham, UK., Cook G; NIHR (Leeds) MIC, Leeds, St James's Teaching Hospital, University of Leeds, Leeds, UK., Purshouse K; Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK., Aries J; Barts Health NHS Trust, London, UK., Innes A; Imperial College Healthcare NHS Trust, London, UK., Cook LB; Imperial College Healthcare NHS Trust, London, UK., Tomkins O; Leswisham and Greenwich NHS Trust, London, UK., Oram HS; Leswisham and Greenwich NHS Trust, London, UK., Tilby M; Queen Elizabeth Hospital, Birmingham, UK., Kulasekararaj A; Department of Haematology, King's College Hospital, London, UK., Wrench D; Guys and St Thomas' NHS Foundation Trust, London, UK., Dolly S; Guys and St Thomas' NHS Foundation Trust, London, UK., Newsom-Davies T; Chelsea and Westminster Hospital NHS Foundation Trust, London, UK., Pettengell R; St Georges University Hospitals NHS Foundation Trust, London, UK., Gault A; NCCC Northern Centre for Cancer Care, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK., Moody S; NCCC Northern Centre for Cancer Care, The Newcastle Upon Tyne NHS Foundation Trust, Newcastle, UK., Mittal S; Northampton General Hospital NHS Trust, Northampton, UK., Altohami M; Northampton General Hospital NHS Trust, Northampton, UK., Tillet T; Royal United Hospitals Bath, Bath, UK., Illingworth J; Barking, Havering and Redbridge University Hospitals NHS Trust, Essex, UK., Mukherjee L; Beatson West of Scotland Cancer Centre, Glasgow, UK., Apperly J; Imperial College Healthcare NHS Trust, London, UK., Ashcroft J; NIHR (Leeds) MIC, Leeds, St James's Teaching Hospital, University of Leeds, Leeds, UK.; Mid Yorkshire Hospitals NHS Trust, Wakefield, UK., Rabin N; University College London Hospitals, London, UK., Carmichael J; NIHR (Leeds) MIC, Leeds, St James's Teaching Hospital, University of Leeds, Leeds, UK., Cazier JB; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.; Centre for Computational Biology, University of Birmingham, Birmingham, UK., Kerr R; Department of Oncology, Oxford University, Oxford, UK., Middleton G; Institute of Immunology and Immunotherapy, University of Birmingham, Edgbaston, Birmingham, UK., Collins GP; Oxford NIHR Biomedical Research Centre, Department of Haematology, Churchill Hospital, Oxford, UK., Palles C; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2022 Feb; Vol. 196 (4), pp. 892-901. Date of Electronic Publication: 2021 Nov 10.
DOI: 10.1111/bjh.17937
Abstrakt: Patients with haematological malignancies have a high risk of severe infection and death from SARS-CoV-2. In this prospective observational study, we investigated the impact of cancer type, disease activity, and treatment in 877 unvaccinated UK patients with SARS-CoV-2 infection and active haematological cancer. The primary end-point was all-cause mortality. In a multivariate analysis adjusted for age, sex and comorbidities, the highest mortality was in patients with acute leukaemia [odds ratio (OR) = 1·73, 95% confidence interval (CI) 1·1-2·72, P = 0·017] and myeloma (OR 1·3, 95% CI 0·96-1·76, P = 0·08). Having uncontrolled cancer (newly diagnosed awaiting treatment as well as relapsed or progressive disease) was associated with increased mortality risk (OR = 2·45, 95% CI 1·09-5·5, P = 0·03), as was receiving second or beyond line of treatment (OR = 1·7, 95% CI 1·08-2·67, P = 0·023). We found no association between recent cytotoxic chemotherapy or anti-CD19/anti-CD20 treatment and increased risk of death within the limitations of the cohort size. Therefore, disease control is an important factor predicting mortality in the context of SARS-CoV-2 infection alongside the possible risks of therapies such as cytotoxic treatment or anti-CD19/anti-CD20 treatments.
(© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: